Apr. 21 at 2:10 AM
$MIST
From the 10K and with Gemini's assistance (Google's AI), I did my best to gather together basic midpoint rough prescription estimates for three markets for peak years. The numbers add up especially because I've included AFib-RVR. On the other hand, some of the imput is lower than expected. For example, while there are far more AFib-RVR cases than for PSVT, the number of prescriptions per user is much lower. Also, outside of the USA, a far lower percentage of cases get diagnosed and insurance payouts are far lower. The numbers of prescriptions are in millions, the dollars are as is. First is the total, followed by breakdown of the PSVT and AFib-RVR parts, last is the insurance payout per prescription.
USA: 6.55 (3.25 + 3.30) X
$850 =
$5,567,500,000.
Europe: 6.90 (3.10 + 3.80) X
$265 =
$1,828,500,000.
Japan: 2.85 (1.35 + 1.50) X
$215 =
$612,750,000.
Average drug company Market Capitalization = 6.47 X Sales.
$8,008,750,000 X 6.47 =
$51,816,612,500.
